OUR SCIENCE

Eupraxia’s proprietary Diffusphere™ technology is designed to deliver medications directly to targeted tissues, aiming to provide sustained therapeutic levels while minimizing systemic exposure*.

Our Diffusphere™ Technology

Imprecise drug delivery often limits a drug’s safety and efficacy. Conventional delivery exposes both healthy and disease tissues, increasing side effects and reducing efficacy. Frequent dosing is often required to manage this issue, increasing patient burden.

Eupraxia’s proprietary Diffusphere™ technology aims to improve therapies by delivering the right dose of drug, in the right place and for the right duration.

Diffusphere coats an active compound with a micron-thin polymer membrane designed to release this drug core at a defined, constant rate as it dissolves.

Other extended-release approaches mix a small amount of drug in a large polymer matrix. The drug then often releases unevenly as the polymer dissolves, potentially reducing tolerability and efficacy.

With a more controlled, local release, Diffusphere aims to improve therapies duration, efficacy and side effects profile.

Eupraxia is developing EP-104GI for the treatment of Eosinophilic Esophagitis

What is Eosinophilic Esophagitis (EoE)?*

In EoE, inflammatory white blood cells infiltrate the esophagus, leading to:

Pain and difficulty swallowing

Food stuck in the esophagus, necessitating emergency visits

Anxiety and depression

Long-term risk of esophageal remodeling of the esophagus and strictures, if left untreated or incompletely treated

EoE has seen a significant increase in prevalence:*

Global cases have seen a sharp rise in recent years

US prevalence: 1 in 700 individuals (142.5 per 100,000)

Projected emergency visits by 2030: Over 15,000 annually

Treatment challenges in EoE:*

Swallowed corticosteroids used in the treatment of EoE lead to a short contact with the esophagus

Current standards of care in EoE overall result in poor adherence, with over 40% of patients non-compliant with their treatment

EP-104GI in EoE

EP-104GI, as a long-acting submucosal corticosteroid formulation to be injected within esophageal tissues has the potential to increase patient adherence by requiring fewer interventions, while addressing local inflammation.

EP-104GI is currently being studied in the RESOLVE Phase 1b/2 clinical trial.

Scientific Publications

Digestive Disease Week 2026, May 2 Chicago, IL
Durability of Dysphagia Improvements Following Single Administration of EP-104GI in Participants With Eosinophilic Esophagitis During Dose Escalation in the RESOLVE Trial
Albert J. Bredenoord, Nahm Nguyen, Vincent Ho, Hin Hin Ko, Waqqas Afif, Gerald Holtmann, Evan Dellon, Tyler Kolisnik, Andrew Dye, Amanda Malone, Mark Kowalski
Digestive Disease Week 2026, May 2 Chicago, IL
Single Administration of EP-104GI in RESOLVE, a Phase 1b/2 Trial in Eosinophilic Esophagitis, Improves Endoscopic Features of Inflammation and Fibrosis Over 36 Weeks
Nirmala Gonsalves, Nahm Nguyen, Hin Hin Ko, Vincent Ho, Waqqas Afif, Gerald Holtmann, Evan Dellon, Pranali Ravikumar, Andrew Dye, Amanda Malone, Mark Kowalski
Digestive Disease Week 2026, May 2 Chicago, IL
RESOLVE: A Phase 1b/2 Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EP-104GI in Adults with Eosinophilic Esophagitis
Evan Dellon, Albert J. Bredenoord. Nirmala Gonsalves, Stephen Attwood, Roos Pouw, Chris Ma, Andrew Dye, Mark Kowalski, Amanda Malone
Digestive Disease Week 2026, May 2 Chicago, IL
Single Administration of Escalating Doses of EP-104GI Leads to Persistent Improvements in Histological Features of Eosinophilic Esophagitis Over 36 Weeks in RESOLVE, a Phase 1b/2 Dose Escalation and Optimization Trial
Christopher Ma, Nam Nguyen, Hin Hin Ko, Vincent Ho, Waqqas Afif, Gerald Holtmann, Evan S. Dellon, Christine Dobek, Andrew Dye, Mark Kowalski, Amanda Malone
Asian Pacific Digestive Week 2025, November 18 Singapore
Updated Results from RESOLVE; Ongoing Study of EP-104GI (Long-acting Fluticasone Propionate Injection) For Eosinophilic Esophagitis
Nahm Nguyen, James Helliwell, Mark M. Kowalski, Hin Hin Ko, Waqqas Afif, Gerald Holtmann, Albert J. Bredenoord, Evan S. Dellon, Christine Dobek, Pranali Ravikumar, Vik Peck, Amanda Malone
American College of Gastroenterology Annual Scientific Meeting 2025, October 29 Phoenix, Arizona
Persistent Improvement in Dysphagia Symptoms for 52 Weeks Following a Single Administration of EP-104GI in RESOLVE, an Ongoing Phase 1b/2 Trial in Eosinophilic Esophagitis
Evan S. Dellon, Waqqas Afif, Nahm Nguyen, Hin Hin Ko, Albert J. Bredenoord, Vik Peck, Amanda Malone, Mark M. Kowalski
American College of Gastroenterology Annual Scientific Meeting 2025, October 24 Phoenix, Arizona
Results from Dose Escalation Cohorts 1-6 of RESOLVE, an Ongoing Phase 1b/2a Study of EP-104GI (Long-acting Fluticasone Propionate Injectable Suspension) For Eosinophilic Esophagitis
Amanda Malone, James Helliwell, Mark M. Kowalski, Nahm Nguyen, Hin Hin Ko, Waqqas Afif, Gerald Holtmann, Albert J. Bredenoord, Christine Dobek, Pranali Ravikumar, Vik Peck, Evan S. Dellon
United European Gastroenterology 2025, October 4 Berlin, Germany
Results from RESOLVE, An Ongoing Phase 1b/2a Study of EP-104GI (Long-Acting Fluticasone Propionate Injectable Suspension) For Eosinophilic Esophagitis: Dose Escalation Cohorts 3 Through 6
Amanda Malone, James Helliwell, Mark M. Kowalski, Nahm Nguyen, Hin Hin Ko, Waqqas Afif, Gerald Holtmann, Christine Dobek, Evan S. Dellon, Albert J. Bredenoord
World Congress of Gastroenterology @ Australian Gastroenterology Week 2025, September 19 Melbourne, Australia
Updated Dose Escalation Results From RESOLVE, An Ongoing Phase 1b/2a Study of EP-104GI (Long-Acting Fluticasone Propionate Injectable Suspension) For Eosinophilic Esophagitis
Nahm Nguyen, Amanda Malone, James Helliwell, Mark M. Kowalski, Hin Hin Ko, Gerald Holtmann, Waqqas Afif, Albert J. Bredenoord, Evan S. Dellon, Christine Dobek, Pranali Ravikumar, Vik Peck
Digestive Disease Week 2025, May 3 San Diego, CA
Prevalence and Causes of Severe Esophageal Strictures Requiring Multiple Dilations in the United States

Catherine Byrne, Chelsea Anderson, Paul Brennan, Amanda Malone, Christina Roberts-Smith, Mark M. Kowalski, Vick Peck, Evan S. Dellon
Digestive Disease Week 2025, May 3 San Diego, CA
Results From Dose Escalation From RESOLVE, an Ongoing Phase 1b/2a Study of EP-104GI (Long-acting Fluticasone Propionate Injectable Suspension) For Eosinophilic Esophagitis
Amanda Malone, James Helliwell, Mark M. Kowalski, Nahm Nguyen, Hin Hin Ko, Christine Dobek, Vik Peck, Evan S. Dellon
American College of Rheumatology Convergence 2024, November 14 Washington, D.C.
EP-104IAR (Long-Acting Intra-Articular Injection of Fluticasone Propionate) Shows Sustained Improvement in Pain for Subjects with Moderate Baseline Pain and BMI Less Than 30 in SPRINGBOARD, a Phase 2, Randomized, 24-Week Study of Osteoarthritis of the Knee
Amanda Malone,James Helliwell, Mark Kowalski, Helene Rovsing, Sidsel Lynggaard Boll, Asger Reinstrup Bihlet, Claire P. Miller, Alejandro Castillo Mondragon, Yanqi Li, Kathrine Moriat, Christine Dobek, Vik Peck, Andrew Dye, Mike Wilmink, Lee S. Simon, Philip Conaghan
American College of Gastroenterology Annual Scientific Meeting 2024, October 25 Philadelphia, PA
Pharmacokinetics and Local Tolerability of EP-104GI, an Extended-Release Formulation of Fluticasone for Treatment of Eosinophilic Esophagitis, after Intra-Esophageal Injection in Mini-Pigs
Murray Webb, Ana Litke, Catherine Byrne, Liam MacFarlane, Amanda Malone
American College of Gastroenterology Annual Scientific Meeting 2024, October 25 Philadelphia, PA
Efficacy and Pharmacokinetic Results From Ongoing Dose Escalation in RESOLVE, a Phase 1b/2a Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis
Amanada Malone, James Helliwell, Mark M. Kowalski Albert J. Bredenoord, Nahm Nguyen, Hin Hin Ko, Christine Dobek, Vick Peck, Evan S. Dellon
United European Gastroenterology Week 2024, October 12 Vienna, Austria
Results from dose escalation in RESOLVE, an ongoing Phase 1b/2a dose-escalation study of EP-104GI (extended-release fluticasone propionate intra-esophageal injection) for eosinophilic esophagitis.
James Helliwell, Amanada Malone, Mark M. Kowalski, Albert J. Bredenoord, Nahm Nguyen, Hin Hin Ko, Christine Dobek, Ana Litke, Vick Peck, Murray Webb, Evan S. Dellon
ISDE 2024, September 22 Edinburgh, Scotland
Initial Results from RESOLVE, a Phase 1b/2a Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis
James Helliwell, Amanada Malone, Mark M. Kowalski, Albert J. Bredenoord, Nahm Nguyen, Hin Hin Ko, Christine Dobek, Vick Peck, Evan S. Dellon
Digestive Disease Week 2024, May 18 Washington, D.C.
Initial Results From RESOLVE, an Ongoing Phase 1b/2a Dose-escalation Study of EP-104GI (Long-acting Fluticasone Propionate Injectable Suspension) For Eosinophilic Esophagitis
James Helliwell, Amanada Malone, Mark M. Kowalski, Albert J. Bredenoord, Nahm Nguyen, Hin Hin Ko, Christine Dobek, Vick Peck, Evan S. Dellon
Osteoarthritis Research Society International World Congress 2024, April 18 Vienna, Austria
EP-104IAR (extended-release intra-articular injection of fluticasone propionate) shows sustained pain response for subjects with moderate baseline pain and BMI less than 30 in SPRINGBOARD, a Phase 2, randomized, 24-week study of osteoarthritis of the knee
Amanda Malone, James Helliwell, Mark Kowalski, Helene Rovsing, Sidsel Lynggaard Boll, Asger Reinstrup Bihlet, Claire P. Miller, Alejandro Castillo Mondragon, Yanqi Li, Kathrine Moriat, Christine Dobek, Vik Peck, Andrew Dye, Mike Wilmink, Lee S. Simon, Philip Conaghan
PAINWeek 2023, September 5 Las Vegas
EP-104IAR (Long-Acting Intra-Articular Injection of Fluticasone Propionate): Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in 318 Subjects with Knee Osteoarthritis
James Helliwell, Amanda Malone, Mark Kowalski, Christine Dobek
Lancet Rheumatology 2024 6:e860-70
Efficacy and safety of a diffusion-based extended-release fluticasone propionate intra-articular injection (EP-104IAR) in knee osteoarthritis (SPRINGBOARD): a 24-week, multicentre, randomised, double-blind, vehicle-controlled, phase 2 trial
Amanda Malone, Mark M Kowalski, James Helliwell, Sidsel Lynggaard Boll, Helene Rovsing, Kathrine Moriat, Alejandro Castillo Mondragón, Yanqi Li, Claire Prener Miller, Asger Reinstrup Bihlet, Christine Dobek, Vik Peck, Mike Wilmink, Lee S Simon, Philip G Conaghan
Osteoarthritis and Cartilage Open 2021 100213
Safety and pharmacokinetics of EP-104IAR (sustained-release fluticasone propionate) in knee osteoarthritis: A randomized, double-blind, placebo-controlled phase 1 trial

Amanda Malone, James Price, Nicola Prica, Vik Peck, Alan Getgood, Robert Petrella, James Helliwell
Cartilage 2019 10(2) 139–147
Pharmacokinetic Profile of Intra-articular Fluticasone Propionate Microparticles in Beagle Dog Knees
Alan Getgood, Aad Dhollander, Amanda Malone, James Price, and James Helliwell
LifeSci Events webinar 2025
KOL event with guest, Dr. Evan Dellon, to discuss data from the RESOLVE trial
Dr. Evan Dellon, Dr. James A. Helliwell
European Medical Journal 7.3 2022 46-50
Tackling Unmet Medical Need: How Slow-Release Intra-articular Corticosteroids Could Play a Role in Improving Quality of Life and Reducing Risk in Osteoarthritis
Dr. Phillip Conaghan, Dr. Lee S. Simon